Episode Details

#Ozempic #Wegovy #GLP1 #WeightLoss #obesitymedicine 

Nausea, constipation, bloating, gas — if you're on semaglutide (Ozempic or Wegovy), gastrointestinal side effects are the most common thing you'll run into. In this video, I break down exactly why they happen and the specific, evidence-based strategies that actually reduce them: portion sizes, meal timing, which foods make it worse, hydration, injection timing, dose titration, and the red flags that mean it's time to call your doctor — not internet folklore, actual clinical data and two decades of hospital medicine.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
Live Q&As, evidence-based education, accountability, workouts, nutrition guidance & community support.
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS
0:00 – Intro & Disclaimer
1:35 – What Semaglutide Actually Is (and Why Side Effects Happen)
3:22 – Tip 1: Cut Your Portions
5:14 – Tip 2: Smaller, More Frequent Meals
6:27 – Tip 3: Foods That Work Against You
8:04 – Tip 4: Hydration & Constipation
9:04 – Tip 5: Time Your Injection Around Your Life
9:45 – Tip 6: Injection Site — Myth vs. Evidence
11:38 – Tip 7: Titration Schedule
12:34 – The Symptom Timeline: When It Gets Better
13:35 – When to Call Your Doctor
14:39 – The Bigger Picture
16:01 – Resources & Next Steps

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002. — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine. 2022;134(1):14-19. — https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025. — https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clinic Proceedings. 2025. — https://www.mayoclinicproceedings.org/article/S0025-6196(25)00551-8/fulltext
Novo Nordisk. Ozempic (semaglutide) injection Prescribing Information. — https://www.novo-pi.com/ozempic.pdf
Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information. — https://www.novo-pi.com/wegovy.pdf
FDA Clinical Pharmacology Review, NDA 215866 (tirzepatide) — injection site bioequivalence data, cited in the corrected Tip 6. — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000ClinPharmR.pdf

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with yo